Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma. Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results